By Michael Dabaie

 

AbbVie Inc. (ABBV) said Skyrizi met the primary and all ranked secondary endpoints, including superiority at week 52, versus Cosentyx in a head-to-head Phase 3 study in adults with moderate to severe plaque psoriasis.

Skyrizi showed significantly higher rates of skin clearance compared with Cosentyx, meeting the primary endpoint of superiority with at least a 90% improvement from baseline in the Psoriasis Area and Severity Index at week 52, AbbVie said.

AbbVie shares were up 1% to $87.64 premarket trade Tuesday.

The safety profile of Skyrizi was consistent with that observed in previously reported studies, with no new safety signals observed through week 52, the company said.

Skyrizi is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 

(END) Dow Jones Newswires

January 14, 2020 09:22 ET (14:22 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Aug 2020 to Sep 2020 Click Here for more AbbVie Charts.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Sep 2019 to Sep 2020 Click Here for more AbbVie Charts.